You are here: Industry Insights > Daiichi Sankyo

News List

Pharmaceutical News of the Week | CPhI.CN - Transactions PharmaSources/Caicai
August 06, 2020
Daiichi Sankyo announced on July 27 that it entered into a global cooperation and development agreement with AstraZeneca for Daiichi Sankyo’s DS-1062.
Enhertu improves progression-free survival in breast cancer trial pharmatimes
August 09, 2021
Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conjugate (ADC) ADC demonstrated superiority over trastuzumab emtansine (T-DM1).
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC pharmatimes
May 11, 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ACD) datopotamab deruxtecan has demonstrated 'promising' preliminary response and disease control in new data evaluating the therapy among patients with metastatic triple negative breast ...
Daiichi Sankyo’s cholesterol-lowering drugs recommended for NHS use pharmatimes
April 30, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Daiichi Sankyo’s cholesterol drugs Nilemdo and Nustendi for use on the NHS, benefitting around 70,000 adults in England with high cholesterol.
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer pharmatimes
April 21, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu for use within the cancer drugs fund (CDF) for the treatment of previously-treated HER2-positive metastatic breast cancer.
Daiichi Sankyo inks digital partnership for atrial fibrillation pharmatimes
March 24, 2021
Daiichi Sankyo has signed a collaborative agreement with three technology partners to improve the detection and diagnosis of atrial fibrillation (AF) in the UK.
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments pharmatimes
March 18, 2021
Daiichi Sankyo’s cholesterol-lowering drugs Nilemdo and Nustendi have been approved by the UK National Institute for Health and Care Excellence (NICE) for use on the NHS.
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK pharmatimes
February 19, 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials pharmatimes
January 29, 2021
AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.
Enhertu bags EU approval for HER2-positive breast cancer pharmatimes
January 21, 2021
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been granted a conditional approval in the EU.

Previous page 1 2 3 4 5 6 7 8 Next page